Scoring and Reporting HER2 Solid Tumors

CE / CME

Refining Approaches to Overcome Challenges, Enhance Consistency, and Standardize Scoring and Reporting in HER2-Expressing Solid Tumors

Physicians: Maximum of 1.25 AMA PRA Category 1 Credits

ABIM MOC: maximum of 1.25 Medical Knowledge MOC points

ABPath MOC: maximum of 1.25 Lifelong Learning points

Released: April 21, 2025

Expiration: October 20, 2025

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Which of the following pathology findings related to HER2 alterations would you flag as actionable with an approved targeted therapy for patients with previously treated advanced NSCLC?

2.

Which of the following staining patterns would constitute a HER2 IHC 2+ finding in a tumor cell cluster of a gastric cancer biopsy sample, suggesting the need for additional FISH testing?

3.

For patients with HER2 IHC 3+ metastatic biliary tract cancer that has progressed after first-line gemcitabine/cisplatin + immunotherapy, which of the following would be an FDA-approved option for targeted therapy?